NCT06038916

To Evaluate The Safety and Initial Efficacy of STSA-1002 Injection in Patients With Acute Respiratory Distress Syndrome

Phase Ib/II Randomized, Double-blind, Placebo-controlled Evaluation of the Safety and Initial Efficacy of STSA-1002 Injection in Patients With Acute Respiratory Distress Syndrome

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 47 (actual)
• Sponsor: Staidson (Beijing) Biopharmaceuticals Co., Ltd · Industry
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the safety and initial efficacy of STSA-1002 injection in patients with acute respiratory distress syndrome.

Conditions

• Acute Respiratory Distress Syndrome

Interventions

Type	Name	Description
DRUG	STSA-1002 Injection Placebo	Intravenous infusion
DRUG	STSA-1002 Injection	Intravenous infusion

Timeline

• Start date: 2023-12-09
• Primary completion: 2025-03-20
• Completion: 2025-04-27
• First posted: 2023-09-15
• Last updated: 2025-07-11

Locations

30 sites across 1 country: China